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Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global health problem that causes millions of deaths
worldwide. The clinical manifestation of COVID-19 widely varies from asymptomatic infection to severe pneumonia
and systemic inflammatory disease. It is thought that host genetic variability may affect the host’s response to the
virus infection and thus cause severity of the disease. The SARS-CoV-2 virus requires interaction with its receptor
complex in the host cells before infection. The transmembrane protease serine 2 (TMPRSS2) has been identified as
one of the key molecules involved in SARS-CoV-2 virus receptor binding and cell invasion. Therefore, in this study,
we investigated the correlation between a genetic variant within the human TMPRSS2 gene and COVID-19 severity
and viral load.
Results: We genotyped 95 patients with COVID-19 hospitalised in Dr Soetomo General Hospital and Indrapura Field
Hospital (Surabaya, Indonesia) for the TMPRSS2 p.Val160Met polymorphism. Polymorphism was detected using a
TaqMan assay. We then analysed the association between the presence of the genetic variant and disease severity
and viral load. We did not observe any correlation between the presence of TMPRSS2 genetic variant and the
severity of the disease. However, we identified a significant association between the p.Val160Met polymorphism
and the SARS-CoV-2 viral load, as estimated by the Ct value of the diagnostic nucleic acid amplification test.
Furthermore, we observed a trend of association between the presence of the C allele and the mortality rate in
patients with severe COVID-19.
Conclusion: Our data indicate a possible association between TMPRSS2 p.Val160Met polymorphism and SARS-CoV-
2 infectivity and the outcome of COVID-19.
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Background
Coronavirus disease 2019 (COVID-19) is the biggest
pandemic in the twenty-first century so far. Since the
declaration of the pandemic by the World Health
Organization (WHO), more than 110 million cases with
more than 2.4 million deaths worldwide have been re-
corded as per mid-February 2021 [1]. COVID-19 is
caused by an infection with the SARS-CoV-2 virus,
which typically infects cells in the respiratory tract. The
clinical presentations of COVID-19 range widely from
asymptomatic infection to lethal pneumonia. It is known
that three major factors, i.e. age, gender and the pres-
ence of underlying diseases, play a major role in deter-
mining COVID-19 severity [2–4]. However, it is not
clear whether genetic variability contributes significantly
to the clinical outcomes of COVID-19 patients.
One important factor that may play a crucial role in
determining COVID-19 severity is the interaction be-
tween the virus and the host cells. SARS-CoV-2 infects
the host cells by binding with its receptor on the surface
of the host cell membrane. The main receptor for the
SARS-coronavirus family is the angiotensin-converting
enzyme 2 (ACE2) [5]. It is known that the spike (S) pro-
tein of SARS-CoV-2 mediates the binding of the virus to
the ACE2 protein [6]. Considering the importance of
virus receptor binding during the infection, it is logical
to hypothesise that genetic variations within the gene
encoding ACE2 may be associated with the degree of in-
fection and hence the severity of the disease. Surpris-
ingly, studies have reported no correlation between the
genetic variations in the human ACE2 gene and the se-
verity of COVID-19 [7], as well as the previous severe
acute respiratory syndrome (SARS) [8].
In addition to ACE2, several other molecules are also
involved in the process of SARS-CoV-2 virus entry. For
example, transmembrane protease serine 2 (TMPRSS2)
[9] and neuropilin-1 (NRP1) [10] have been identified as
co-receptors for SARS-CoV-2 that play a crucial role
during virus entry. These molecules are important in
mediating virus entry; for example, TMPRSS2 is known
to facilitate the cleavage of the S protein, enabling mem-
brane fusion and endocytic entry of the virus particles
[11]. This has prompted us to hypothesise that genetic
variability within the TMPRSS2 gene may play a role in
determining SARS-CoV-2 infection.
A recent analysis based on computational modelling
suggested that out of more than eleven thousand single
nucleotide polymorphisms (SNPs) within the human
TMPRSS2 gene (dbSNP, NCBI) only 21 SNPs with
minor allele frequency (MAF) between 0.01 and 0.95
were predicted to affect the function of the protein [12].
Of these 21 SNPs, only two SNPs are missense variants
(rs12329760 and rs75603675). The rs12329760 poly-
morphism (also known as p.Val160Met variant) has been
shown in several studies to play a role in mediating the
risk for prostate cancer, confirming clinical conse-
quences of this genetic variant [13–16]. Therefore, in
this study, we focused on studying the association be-
tween the p.Val160Met variant of the TMPRSS2 gene
and the severity, viral load and clinical outcomes of
COVID-19 patients. Although we did not find any cor-
relation between the p.Val160Met polymorphism and
disease severity, we observed a possible association be-
tween the TMPRSS2 pVal160Met variant and the viral
load in COVID-19 patients.
Results
Characteristics of patients
Characteristics of COVID-19 patients included in this
study are described in Table 1. Age distributions were
significantly different between patients with asymptom-
atic and mild versus moderate and severe COVID-19.
There was a significant difference in the sex distribution
with a higher proportion of male patients in the symp-
tomatic groups. Significant differences were observed in
the proportions of patients with underlying diseases be-
tween the asymptomatic and mild patients versus mod-
erate and severe groups. As expected, the patients in the
asymptomatic and mild COVID-19 groups displayed a
significantly lower frequency of underlying diseases
compared with the moderate and severe groups, includ-
ing diabetes (P value < 0.001), cardiovascular disease (P
value = 0.009) and liver disease (P value = 0.007).
TMPRSS2 p.Val160Met polymorphism and COVID-19
severity
The TMPRSS2 p.Val160Met polymorphism (rs12329760)
was successfully detected in all patients. The genotype and
allele frequencies of this SNP are shown in Additional file
1. We observed a deviation of the allele frequency from
Hardy–Weinberg equilibrium (χ2 = 6.72, P value = 0.035).
However, the frequency of C allele (61.6%) and T allele
(38.4%) in this study population seemed to be comparable
with the reported frequency in the Asian population
(dbSNP, NCBI) (Additional file 1).
The cross-tab analysis for the genotype and severity
groups indicated no significant difference in the distribu-
tion of TMPRSS2 p.Val160Met polymorphism among
the four groups of patients (Table 2). There were higher
odds ratios in subjects with CC and CT genotypes to get
symptomatic or more severe COVID-19 than those with
TT genotype although they did not reach statistical sig-
nificance (Table 3).
TMPRSS2 p.Val160Met polymorphism and viral load
Next, we analysed the association between polymorph-
ism and the viral load. All of the patients had positive re-
sults of the nucleic acid amplification testing (NAAT)
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for the SARS-CoV-2 virus. The Ct value was used as the
semi-quantitative predictor of the viral load. Since Ct
values vary depending on the qPCR system and the
methodology of the NAAT, we only focused our analysis
on patients with moderate and severe COVID-19. All of
the patients in these groups were hospitalised in Dr Soe-
tomo General Academic Hospital; hence, the NAAT was
conducted in the same place, i.e. the Clinical Pathology
and Microbiology Laboratory, Dr Soetomo General Aca-
demic Hospital. We analysed the Ct values of the first
NAAT, which were conducted at the time when the pa-
tients were admitted to the hospital. A low Ct value is
likely associated with a high viral load, whereas a high
Ct value is likely to be associated with a low viral load.
As illustrated in Fig. 1a, a significant difference was ob-
served in the Ct value between patients with a TT geno-
type and patients with a CC genotype (P = 0.04),
indicating a possible association of this genotype with a
higher viral load. The Pearson correlation analysis also
indicated a trend of decreasing Ct value with the pres-
ence of the C allele (P = 0.08). In contrast, we did not
observe any difference and correlation between Ct value
and patients’ gender (Fig. 1b) as well as between Ct value
and age (Fig. 1c). Additionally, there was no difference
in Ct value between patients with moderate and severe
COVID-19 (Fig. 1d).
TMPRSS2 polymorphism and patients’ outcome
During the course of the study, all of the patients with
mild COVID-19 recovered, whereas 9.4% of the
patients with moderate COVID-19 and 60% of the
patients with severe COVID-19 died. When we ana-
lysed the association between TMPRSS2 p.Val160Met
polymorphism and the patients’ outcomes, we did not
find any association between the polymorphism and
mortality in the moderate COVID-19 group (Table 4).
However, we observed a trend of association in the se-
vere group, in which a higher proportion of patients
who died of COVID-19 had a CC genotype (P = 0.042
using the linear-by-linear association chi-squared test)
(Table 4). We also observed an increasing trend of odds














Age (years) 33.9 ± 2.4* 35.6 ± 2.7* 52.3 ± 2.1 48.8 ± 1.5 44.7 ± 1.3 *P<0.001 versus moderate
and severe groups (ANOVA)
Gender (%)
Male 8 (38.1%) 10 (83.3%) 19 (59.4%) 23 (76.7%) 60 (63.2%) 0.016
Female 13 (61.9%) 2 (16.7%) 13 (40.6%) 7 (23.3%) 35 (36.8%)
Underlying diseases (%)
Diabetes 0 0 9 (28.1%) 12 (40%) 21 (22.1%) <0.001
CVD 2 (9.5%) 0 13 (40.6%) 10 (33.3%) 25 (26.3%) 0.009
Liver diseases 0 0 4 (12.5%) 9 (30%) 13 (13.7%) 0.007
Kidney diseases 0 0 4 (12.5%) 1 (3.3%) 5 (5.3%) 0.144
Lung diseases 0 0 3 (9.4%) 0 3 (3.2%) 0.107
Others 0 0 3 (9.4%) 2 (6.7%) 5 (5.3%) 0.386
Table 2 Genotype and allele frequencies of the TMPRSS2 p.Val160Met polymorphism according to COVID-19 severity
Asymptomatic (N=21) Mild (N=12) Moderate (N=32) Severe (N=30) Chi-square
test
N % N % N % N %
Genotype (amino acids)
CC (Val/Val) 8 38.1 4 33.3 17 53.1 13 43.4 χ2= 3.11
CT (Val/Met) 7 33.3 5 41.7 11 34.4 10 33.3 P=0.79
TT (Met/Met) 6 28.6 3 25 4 12.5 7 23.3
Allele
C Allele 23 54.8 13 54.2 45 70.3 36 60 χ2= 3.51
T Allele 19 45.2 11 45.8 19 29.7 24 40 P=0.32
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ratios of mortality in subjects with CC and CT geno-
types (Table 5).
Discussion
This is the first study to demonstrate a possible associ-
ation between TMPRSS2 p.Val160Met polymorphism
and the degree of SARS-CoV-2 viral load as indicated by
the Ct value of NAAT in patients with COVID-19.
Patients with a CC genotype, which corresponds to the
presence of valine amino acid, tend to display a lower Ct
value (high viral load). We also found a trend of associ-
ation between a CC genotype and mortality in a group
of patients with severe COVID-19.
It is widely known that the SARS-CoV-2 virus enters
the host cells via binding with ACE2, which acts as the
main receptor for the viral particles [6, 9, 17]. The spike
Table 3 Analysis of odds ratio for the risk of symptomatic or more severe COVID-19 in each genotype
Asymptomatic (N=21) vs all symptomatic cases (N=74) Asymptomatic and mild (N=33) vs moderate and severe cases (N=62)
Genotype Odds ratio 95% CI P-value Odds ratio 95% CI P-value
CC 1.821 0.533–6.219 0.335 2.045 0.676–6.185 0.255
CT 1.592 0.447–5.664 0.471 1.432 0.462–4.437 0.573


























































Fig. 1 Analysis of NAAT Ct values of patients with moderate and severe symptoms. a Patients with CC genotype displayed significantly lower Ct
values of NAAT compared with patients with TT genotype (ANOVA with post hoc multiple comparison test). b No difference was observed in Ct
values between male and female patients. c There was no association between age and Ct value. d There was no difference in Ct value between
patients with moderate and severe COVID-19
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(S) protein of the SARS-CoV-2 virus consists of two
sub-units: the S1 sub-unit, which is important for virus
attachment, and the S2 sub-unit, which is essential for
membrane fusion. ACE2 molecule can bind to the S1
protein to promote virus invasion into the host cells [6,
18]. In human, ACE2 is expressed in many organs, such
as the upper respiratory tract, alveolar epithelial cells,
vascular endothelial cells and macrophages [5].
In addition to ACE2, several other molecules are in-
volved in SARS-CoV-2 virus binding and cell penetra-
tion. The S protein needs to be cleaved to activate the
endocytic route of virus entry and to enable membrane
fusion. It has been reported that several host proteases
are involved in the process of S protein breakdown.
These include TMPRSS2, cathepsin L, furin [9] and
NRP1 [10].
TMPRSS2 is a serine protease that can prime the S pro-
tein of SARS-CoV-2 to enable cell penetration [9, 19]. The
expression of TMPRSS2 in VeroE6 cells facilitates SARS-
CoV-2 virus entry and promotes virus invasion [9].
Notably, treatment with the TMPRSS2 inhibitor (camostat
mesylate) significantly reduced SARS-CoV-2 virus infec-
tion [9]. Moreover, TMPRSS2 is also involved in SARS-
CoV-1 virus infection [20], supporting the idea of the
critical role of this molecule in mediating virus entry.
The human TMPRSS2 gene is located in chromosome
21.q22.3. It encodes protein that contains a transmem-
brane domain, low-density lipoprotein receptor class A
(LDLRA) domain, scavenger receptor cysteine-rich
(SRCR) domain and serine protease catalytic domain
[21]. At least six nucleotide variants within the human
TMPRSS2 coding region that cause amino acid substitu-
tions have been identified. These include p.Val160Met,
p.Gly181Arg, p.Arg240Cys, p.Gly259Ser, p.Pro335Leu
and p.Gly432Ala [22]. Of these variants, the p.Val160-
Met variant is often associated with diseases, notably
prostate cancer. A study conducted on a Japanese popu-
lation indicated that the TMPRSS2 p.Val160Met variant
(also known as Met160Val polymorphism) was associ-
ated with the risk of sporadic prostate cancer [16]. Also,
a study conducted on 214 patients with prostate cancer
demonstrated that the T allele of this variant, which is
associated with the presence of Met amino acid, was as-
sociated with TMPRSS2-ERG fusion and, thus, might be
important in prostate cancer pathogenesis [23].
Our data indicate that in our study population the
proportion of the genotypes deviates from the Hardy–
Weinberg equilibrium. This deviation could be due to
natural selection, non-random mating, genetic drift, or
gene flow [24]. In our study population, the deviation
was likely due to the higher number of subjects with CC
and TT genotypes than the expected values (Additional
file 1). However, the frequency of subjects with heterozy-
gous genotype (CT) was lower than the expected value.
Therefore, it is unlikely that the deviation was due to
natural selection or advantages of a specific allele be-
cause the number of subjects with homozygous geno-
types of both the T and C alleles was higher than the
expected values, implying that there was no specific ad-
vantage of either the T or C allele. Thus, it is more likely
that the deviation was due to non-random mating or
genetic drift, which is more likely to occur in a small
study population.
Recent bioinformatic analysis studying the functional
effects of nucleotide variants within the human TMPR
SS2 gene revealed that the p.Val160Met variant was the
Table 4 Association between TMPRSS2 polymorphism with mortality/survival in patients with moderate-severe COVID-19
Moderate COVID-19 (N=32) Severe COVID-19 (N=30)
Recovered (N=29, 90.6%) Died (N=3, 9.4%) Recovered (N=12, 30%) Died (N=18, 60%)
Genotype (amino acids)
CC (Val/Val) 16 (50%) 1 (3.1%) 3 (10 %) 10 (33.3%)
CT (Val/Met) 10 (31.3%) 1 (3.1%) 4 (13.3%) 6 (20 %)
TT (Met/Met) 3 (9.4%) 1 (3.1%) 5 (16.7%) 2 (6.7%)
Chi-square test P=0.498 Chi-square test P=0.109
Linear-by-linear chi-square association test P=0.299 Linear-by-linear chi-square association test P=0.042
Table 5 Analysis of odds ratio for the mortality in moderate and severe COVID-19 patients
Odds ratio of mortality in moderate COVID-19 Odds ratio of mortality in severe COVID-19
Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Genotype
CC 0.188 0.009-3.895 0.241 8.33 1.034-67.14 0.062
CT 0.3 0.014-6.382 0.423 3.75 0.473-29.75 0.335
TT 1 Reference 1 Reference
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most likely variant that might affect TMPRSS2 protein
function and stability [12]. Furthermore, a computa-
tional analysis to predict the effects of polymorphism on
protein structure suggested that the Val160Met substitu-
tion might create a pocket protein by influencing several
amino acid residues, which might affect TMPRSS2
structure and its role in SARS-CoV-2 cell entry [12].
Possible changes in TMPRSS2 function and/or structure
due to the Val160Met substitution might explain our
findings on the association of this SNP with the viral
load in COVID-19 patients. Alteration of TMPRSS2
function/structure will likely affect the binding of the S
protein to ACE2 or the membrane fusion process. Re-
duction in TMPRSS2 enzymatic activity may decrease
the furin cleavage of the S1 protein, which may subse-
quently decrease S2 fusion to the host’s cell membrane.
However, further studies at the molecular level are re-
quired to prove this hypothesis, for example, by generat-
ing recombinant TMPRSS2 proteins bearing the variants
and testing them in an in vitro model of SARS-CoV-2
cell infection.
Despite the association between pVal160Met poly-
morphism and the Ct value, we did not find any correl-
ation between the variant and COVID-19 severity. This
might be due to other confounding factors that strongly
contribute to the severity of COVID-19. It is believed
that factors, such as age [3], gender [25] and pre-existing
diseases (hypertension, diabetes, CVD and lung disease)
[4], strongly correlate with the risk of severe COVID-19.
Further analysis with a larger study population is re-
quired to control these confounding variables. Interest-
ingly, in patients with severe COVID-19, we observed a
trend of association between this polymorphism and the
mortality of COVID-19 patients. However, this requires
further confirmation in studies with a larger sample size.
Several studies have found associations between gen-
etic variations in the patient’s genome and COVID-19
severity. Many of the reported polymorphisms were re-
lated to genes involved in the development of inflamma-
tory response, for example, polymorphisms in genes
related to type 1 interferon immunity [26], polymor-
phisms in X-chromosomal TLR7 [27] and polymor-
phisms within genes involved in the interleukin 1
signalling pathway [28]. Our finding indicates a correl-
ation between polymorphism in the gene encoding the
virus receptor complex, i.e. TMPRSS2, and COVID-19
severity. Our data are consistent with previous reports
on TMPRSS2 polymorphisms and COVID-19 severity.
Initial whole genome analysis of 322 COVID-19 patients
in a Chinese population observed a decreasing allele fre-
quency of the TMPRSS2 rs12329760 variant among pa-
tients with severe disease compared with patients with
mild COVID-19 [28], indicating the importance of
TMPRSS2 in COVID-19. Consistently, studies on Italian
COVID-19 patients also demonstrated the role of gen-
etic polymorphisms within the TMPRSS2 gene in deter-
mining COVID-19 severity. An observation on 133
COVID-19 patients found a difference in frequency of
this variant in the COVID-19 patient cohort compared
with the frequency in the reference databases [29]. In
particular, in-depth analysis of available data from the
COVID-19 Host Genetic Initiative (HGI) [30] suggested
a significant association between TMPRSS2 gene poly-
morphism rs12329760 with severe/hospitalised COVID-
19 [31]. However, further analysis on the available HGI
data (https://app.covid19hg.org/) indicated that there
was no significant association/difference of polymorphic
allele between all SARS-CoV-2-infected subjects and the
general population (P=0.569). This data is in line with
our finding that the polymorphism may have more sig-
nificant effects in severe cases of COVID-19.
Together, all of the data indicate a crucial involvement
of the TMPRSS2 genetic variation, the p.Val160Met
(rs12329760) in particular, in mediating the severity of
COVID-19. This will contribute to the growing body of
evidence on the crucial involvement of the host’s genetic
factor in determining susceptibility to and/or severity of
COVID-19.
Conclusions
In summary, this is the first study to demonstrate a pos-
sible association between TMPRSS2 p.Val160Met poly-
morphism and higher viral load in COVID-19 patients.
The main limitation of our study is its small sample size.
Further large-scale studies are required to validate our
findings. Also, by using the Ct value, we can only have
an estimate of the viral load. Precise determination of
the viral RNA copy number using standard curve qPCR
is required to accurately determine the viral load. Mech-
anistic analysis using a cell culture system is also import-
ant to confirm the effects of p.Val160Met on TMPRSS2
protein function. Nevertheless, our finding may provide
new insights into the possibility of using this polymorph-
ism as a biomarker or predictor for COVID-19 severity/
clinical outcome. Furthermore, our data may also sup-
port the idea of targeting TMPRSS2 in COVID-19 ther-
apy, as has been done in some clinical trials [32].
Methods
Study design, patients and data collection
This study was a cross-sectional study conducted from
June to August 2020. During this period, a total of 95
patients with COVID-19 were enrolled. Patients with
moderate and severe COVID-19 (n = 62, 65.3%) were
hospitalised in Dr Soetomo General Academic Hospital,
Surabaya, Indonesia, whilst 33 patients (34.7%) with
asymptomatic or mild symptoms were treated in Indra-
pura KOGABWILHAN II Hospital, Surabaya, Indonesia.
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The diagnosis was confirmed using the nucleic acid
amplification test (NAAT) of the oro-nasopharyngeal
swab specimens. For patients with moderate and severe
symptoms, the NAAT was performed in the Clinical
Pathology and Microbiology Laboratory, Dr Soetomo
General Academic Hospital, whereas for asymptomatic
patients and patients with mild symptoms, the NAAT
was conducted in the Centre for Health Laboratory,
Surabaya, as part of the standard procedure for COVID-
19 management in East Java Province, Indonesia. This
study obtained ethical approval from the Local Ethics
Committee of Dr Soetomo General Academic Hospital,
Surabaya, Indonesia (0006/LOE/301.4.2/V/2020). All pa-
tients have signed the informed consent and agreed to
participate in this study.
We clustered patients in three categories of disease se-
verity based on criteria according to the WHO Guideline
for COVID-19 Management [33] as follows: (i) mild:
characterised by the presence of COVID-19 symptoms
that meet the case definition of COVID-19 (fever, per-
sistent cough, fatigue, anorexia, shortness of breath, my-
algia, sore throat, nose congestion, headache, diarrhoea,
nausea and vomiting, anosmia, ageusia) without evidence
of viral pneumonia and hypoxia; (ii) moderate: charac-
terized by the presence of the clinical signs of pneumo-
nia but without any signs of hypoxia (SpO2 > 93%); and
(iii) severe: characterized by the presence of the clinical
signs of pneumonia and one of the clinical signs of re-
spiratory distress (respiratory rate > 30×/min, severe re-
spiratory distress, or SpO2 < 93%).
DNA isolation
Heparinized peripheral blood samples were collected
and stored in a −80oC freezer before use. DNA extrac-
tion was performed using the QIAamp® Blood DNA
Midi kit (cat #51185, Qiagen) according to the manufac-
turer’s recommended protocol. DNA concentrations
were determined using a microvolume spectrophotom-
eter (NanoDrop Lite, Thermo Fisher Scientific). The
procedures were conducted in the Biosafety Level 3
(BSL 3) Laboratory in the Institute of Tropical Disease,
Universitas Airlangga, to reduce the risk of COVID-19
transmission.
Polymorphism detection
The TMPRSS2 polymorphism (rs12329760, TMPRSS2
p.Val160Met also known as TMPRSS2 Met160Val poly-
morphism) was detected using a TaqMan SNP genotyp-
ing assay (Cat #4351379, Applied Biosystems, USA) in
accordance with the protocol recommended by the
manufacturer. Genotyping was performed using real-
time polymerase chain reaction (RT-PCR) with VIC and
FAM fluorescent reporters to indicate allelic discrimin-
ation. The 7500 Fast Real-Time PCR System (Applied
Biosystems) was used in conjunction with the 7500 soft-
ware v2.3 (Life Technologies™, Applied Biosystems) to
create the allelic discrimination plot.
Data analysis
Statistical analyses were performed using the IBM SPSS
Statistics Software ver. 23 (IBM Corp.) or GraphPad
Prism ver. 8 (GraphPad Software, LLC). A chi-squared
test was used to examine the Hardy–Weinberg equilib-
riums and to determine the association between categor-
ical variables in the cross-tabulation data. ANOVA with
post hoc multiple comparisons was used to analyse nu-
merical data. A P value less than 0.05 was considered to
be statistically significant.
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